메뉴

검색

Celltrion accelerates to respond to new COVID-19 variant… “Under development of antibody cocktail treatment”

By Global Economic Reporter Ha-rin Lee ; translate by Gounee Yang

기사입력 : 2021-11-30 09:39

center
Celltrion’s COVID-19 treatment ‘Regkirona (regdanvimab)’. Photo=Celltrion
Celltrion will speed up the follow-up project to respond to new COVID-19 variant following the antibody treatment ‘Regkirona (CT-P59, substance name Regdanvimab).’

Celltrion announced on the 29th that it will push for binding the cocktail antibody ‘CT-P63’ that can respond to variants and cocktail inhaled therapeutics, which is currently under development.

‘CT-P63’ is an antibody discovered by Celltrion from the candidate substance for neutralizing antibody early in the development of COVID-19 antibody treatments. It is a different antibody from Regkirona approved by the Ministry of Food and Drug Safety. Celltrion previously conducted global phase 1 clinical trial for CT-P63, which is most effective for variants, and recently ended patient administration.

In addition, Celltrion is developing Regkirona as an inhaled treatment type to diversify methods of administering for COVID-19 antibody treatments and improve patient convenience. Existing intravenous injection type Regkirona can only be administered in hospitals, but inhalation type can greatly improve the patient convenience.

Celltrion is aiming to develop a next-generation COVID-19 treatment that can treat COVID-19 variants by combining two projects that have been carried out.

After securing phase 1 clinical trial data of CT-P63 next month, Celltrion is planning to combine inhalation-type treatment and conduct follow-up clinical trials.


By Global Economic Reporter Ha-rin Lee ; translate by Gounee Yang